296 related articles for article (PubMed ID: 22332547)
1. [The value of von Willebrand factor pro-peptide and ADAMTS13 in diagnosis of thrombotic thrombocytopenic purpura].
Ji J; Liu T; Meng WT; Lu ZP
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Nov; 42(6):807-10. PubMed ID: 22332547
[TBL] [Abstract][Full Text] [Related]
2. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.
Joly B; Stepanian A; Hajage D; Thouzeau S; Capdenat S; Coppo P; Veyradier A
Thromb Res; 2014 Nov; 134(5):1074-80. PubMed ID: 25262108
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and clinical application of a new method for detecting ADAMTS13 activity.
Wang AY; Dong NZ; Ma ZN; Zhang JY; Su J; Ruan CG
Chin Med J (Engl); 2010 Jul; 123(14):1859-63. PubMed ID: 20819568
[TBL] [Abstract][Full Text] [Related]
6. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
Liu F; Lu GY; Dong NZ; Bai X; Su J; Ruan CG
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3190-3. PubMed ID: 16405838
[TBL] [Abstract][Full Text] [Related]
7. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
Starke R; Machin S; Scully M; Purdy G; Mackie I
Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
[TBL] [Abstract][Full Text] [Related]
9. Practical issues in ADAMTS13 testing and emerging therapies in thrombotic thrombocytopenic purpura.
Cataland SR; Wu HM
Semin Hematol; 2011 Oct; 48(4):242-50. PubMed ID: 22000089
[TBL] [Abstract][Full Text] [Related]
10. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Lian EC
Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413
[TBL] [Abstract][Full Text] [Related]
12. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.
Kokame K; Nobe Y; Kokubo Y; Okayama A; Miyata T
Br J Haematol; 2005 Apr; 129(1):93-100. PubMed ID: 15801961
[TBL] [Abstract][Full Text] [Related]
13. [Development and application of a new ADAMTS13 assay for TTP diagnosis].
Kokame K; Miyata T
Rinsho Byori; 2005 Jul; 53(7):639-45. PubMed ID: 16104533
[TBL] [Abstract][Full Text] [Related]
14. [Structure and function of ADAMTS13 protease and its relation with diagnosis and treatment of TTP].
Wang Q; Han Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1157-61. PubMed ID: 25130848
[TBL] [Abstract][Full Text] [Related]
15. Plasma ADAMTS13, von Willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases.
Habe K; Wada H; Ito-Habe N; Hatada T; Matsumoto T; Ohishi K; Maruyama K; Imai H; Mizutani H; Nobori T
Thromb Res; 2012 May; 129(5):598-602. PubMed ID: 22070827
[TBL] [Abstract][Full Text] [Related]
16. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
17. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations.
Zhou W; Tsai HM
Thromb Haemost; 2004 Apr; 91(4):806-11. PubMed ID: 15045144
[TBL] [Abstract][Full Text] [Related]
18. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity.
Kato S; Matsumoto M; Matsuyama T; Isonishi A; Hiura H; Fujimura Y
Transfusion; 2006 Aug; 46(8):1444-52. PubMed ID: 16934083
[TBL] [Abstract][Full Text] [Related]
19. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
[TBL] [Abstract][Full Text] [Related]
20. ADAMTS13 unbound to larger von Willebrand factor multimers in cryosupernatant: implications for selection of plasma preparations for thrombotic thrombocytopenic purpura treatment.
Hori Y; Hayakawa M; Isonishi A; Soejima K; Matsumoto M; Fujimura Y
Transfusion; 2013 Dec; 53(12):3192-202. PubMed ID: 23560518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
